ImetelChat

Kmall, well said. Have lost so many family to cancer, it’s a good time to reflect and hope for the future.

Bridge, thanks for trying to contact me re new Geron patent filing. The PM function on chat can be unwieldy. Will check my private emails as I think you have that address. In any case if it’s an Imet/Venclexa combo it is almost certainly related to AML (we love you Aussies!!).

Kmall, I should have been more specific, I meant their Bayer options! Sorry.

Wonder if their incentive options took a hit

Jay thanks for posting this. No question the competition is there. It’s now a matter of demonstrating longevity, PRs and CRs. Did you see any bone marrow data that you could post?

Keep them coming Kmall, we need some levity…

LWS, you should just get over it. AML has NEVER been cured with anything other than a bone marrow transplant. And you know what the risks and success rates with BMT are. If you are looking for a miracle here consider Lourdes. And yes Kmall, let’s hope that the previous hires do not represent a migra...

Well, we once thought Dr. Rizo’s migration to Geron might be preparatory to an ultimate acquisition by J and J also. But I think this is all wishful thinking especially since Scarlett continues to talk with multiple investors. Perhaps this whole fantasy pharma universe will be acquired by Enron.

Kmall, wrong conclusion. Still plenty of interest re new hires or migration of prior employees elsewhere. Always appreciate the info. In many cases it’s all we got!

Kmall, thanks for calling this to our attention. I always seems to find myself in the role of being a Geron apologist. Trying to find some good, some rationale, when something “bad” or at least something that does not seem to further the goals of the company. To me it always looks bad when a higher ...

My prediction is that the FDA will say it was an internal decision and none of our business. Almost a guarantee that it will not be open for discussion during the approval process.

LWS as far as I know you are the only poster on the board that refers to Imetelstat at a “miracle” medicine. Without getting into hagiography, I think we can all agree it appears to be better than anything out there now.

“To be considered for Priority Review, a drug must address a serious condition and. The drug must demonstrate, through clinical trial data or other scientifically valid information, the potential to provide a significant improvement in safety or effectiveness over existing treatments.” Did Geron fai...

Gwik, I think it’s a legit line of inquiry. To be sure, Geron and collaborators are using some form of computer AI to screen/search/formulate new compounds for research.

EOM

Kmall, right on. So odd that Geron went through submitting tranches of data as they were available to “hasten” the approval process. Fast track? What a euphemism! Total borscht. I did want to mention that with the data emerging about lengthening life, that the life extension clock starts for the tre...

As more data accumulates I think it’s important to keep some perspective here. I am going to put at the top of the list the fact, (and I think we can say fact factually, since the data speaks for itself), that patients who respond to treatment in L/R MDS live longer and live better. Not only that, a...

Woah cow boy , not so fast, there is no evidence that trials are starting anywhere near on the timeline you suggest.

Kmall, my take on the 2035 thing based on nothing is that long term follow up will be required (as with CRISPR).

Thanks for posting this Commsman. I always wondered years ago why Geron had to go through the trouble of getting approval for pediatric MDS (or was it MF) when virtually no children got that particular disease. I asked Geron about it then and was told it was just a requirement from the EU. Now thing...